Shanghai Pudong Gongli Hospital | China
Dr. Mierxiati Abudurexiti is an attending urologist at the Department of Urology, Shanghai Gongli Hospital, Pudong New Area, with strong clinical, translational and pharmaceutical research experience in urological oncology. He completed his Ph.D. in Urology at Fudan University Shanghai Cancer Center (2017–2020), where he investigated fatty acid metabolism and mechanisms of drug resistance in prostate cancer, resulting in multiple English-language publications, including recognition in the 2020 EAU Urethral Cancer Guideline and citation by BMJ. During his doctoral training, he actively contributed to multidisciplinary clinical practice, clinical trial planning, national grant writing, academic conference organization, and earned first-class scholarships and the title of “excellent volunteer.” Following his Ph.D., he worked as a Medical Manager at Jiangsu Hengrui Pharmaceuticals (2020–2021), gaining expertise in clinical trial protocol design, statistical analysis and medical strategy in breast cancer, and directly contributing to the successful HR-BLT-003 trial presented at the 45th San Antonio Breast Cancer Symposium. He subsequently pursued postdoctoral research at the Shanghai Institute of Urological Oncology Laboratory, focusing on prostate cancer heterogeneity and drug resistance through single-cell multi-omics analysis; this led to publication in Advanced Science (IF 15.1) and further strengthened his research foundation in tumor biology. Since 2021, as an attending oncologist, he continues to integrate updated evidence-based oncology practice into patient care, while leading a funded research project on the role of CPT1B in the resistance mechanism of castration-resistant prostate cancer under the Pudong Science & Technology Commission. Earlier in his career, Dr. Mierxiati obtained his Master of Surgery in hepatobiliary surgery from Xinjiang Medical University (2011–2014), publishing early SCI papers on liver hydatid disease, followed by comprehensive standardized surgical training (2014–2016) at Xinjiang People’s Hospital, where he rotated through major surgical specialties and improved his clinical competencies. He later worked as a urology resident (2016–2017) in the same institution, participating in the management of benign and oncologic conditions, discipline-level key application projects, summit forums, and clinical trial implementation. Across his career, he has authored more than 12 peer-reviewed publications covering urological tumors, prognostic modeling, prostate cancer biology, and renal cancer therapy. His consistent focus on clinical innovation, molecular mechanisms of treatment resistance, and enhancement of patient outcomes highlights his commitment to advancing the field of urologic oncology.
Profile: Orcid
Featured Publications
Xu, W., Ye, D., Abudurexiti, M., Zhang, H.*, et al. (2025). Preoperative VEGFR-TKI plus ICI therapy facilitates 3D-guided cytoreductive nephron-sparing surgical feasibility and immune remodeling in advanced renal cell carcinoma. Medical Research, 12, 1–17.
Bian, X., Wang, W., Abudurexiti, M.*, et al., & Wang, J. (2024). Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity. Advanced Science, e2305724.
Abudurexiti, M., Ma, J., Li, Y., et al. (2022). Clinical outcomes and prognosis analysis of younger bladder cancer patients. Current Oncology, 29(2), 578–588.
Wang, J., Abudurexiti, M., Shao, N., et al. (2020). The U-shape of prostate-specific antigen and prostate cancer-specific mortality in high-grade metastatic prostate adenocarcinoma. European Urology Focus, 6(1), 53–62.
Abudurexiti, M., Zhu, Y., & Ye, D. (2020). Locoregional surgical treatment improves the prognosis in primary metastatic testicular cancer patients with a single bone or brain metastasis. Molecular and Clinical Oncology, 6, 146–154.